

D<sup>2</sup>

26. (Amended) [The] A single DNA [of claim 1 further] comprising a nucleic acid sequence coding for cystic fibrosis transmembrane conductance regulator comprising the nucleic acid sequence set forth in Table 1 having at least one intron located within the cystic fibrosis transmembrane conductance regulator coding region.

D<sup>3</sup>

36. (Amended) A low copy number vector comprising DNA [encoding cystic fibrosis transmembrane conductance regulator] which encodes the amino acid sequence of cystic fibrosis transmembrane conductance regulator set forth in Table 1.

D<sup>4</sup>

39. (Amended) The vector of claim [38] 36 comprising the vector pkk-CFTR3.

D<sup>5</sup>

40. (Amended) The vector of claim 36 [further comprising a stabilizing element] wherein the DNA is stabilized against cellular recombination.

D<sup>5</sup>

54. (Amended) A therapeutic composition comprising a carrier comprising [the vector of claim 51] a vector comprising the DNA of claim 1 which after administration, augments the in vivo production or activity of cystic fibrosis transmembrane conductance regulator.

D<sup>6</sup> NOT allow  
Should not have been examined as amendy 4/14

55. (Amended) A host cell comprising the DNA of claim 1, the DNA of claim 26[36], the DNA of claim 36[47], the DNA of claim 48] or the DNA of claim 50.

D<sup>6</sup>

62. (Amended) A host cell comprising a vector containing the DNA of claim [25] 1, the DNA of claim 26, the [vector]DNA of claim [38] 36 or the [vector of claim 42]DNA of claim 50.